newsfilter
← Latest News
Business Wire·

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Atara received FDA Complete Response Letter (CRL) solely related to inspection findings at third-party manufacturer CRL did not identify deficiencies related to clinical efficacy or safety data in the Biologics